Syeda Behjat Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Syeda Behjat Ahmad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Andrew S. Bomback
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
1 shared publicationDominick Santoriello
Department of Pathology, Columbia College of Physicians and Surgeons, New York, NY
1 shared publicationEvan C. Ray
Renal-Electrolyte Division, Department of Internal Medicine, University of Pittsburgh, PA
1 shared publication- Gerald B. Appel
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
1 shared publication Glen Markowitz
Department of Pathology, Columbia College of Physicians and Surgeons, New York, NY
1 shared publication- J. Ashley Jefferson
Division of Nephrology, University of Washington, Seattle, Washington
1 shared publication
Latest Publications
- 4 June 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1844-1857
Targeting B Cells and Plasma Cells in Glomerular Disease
Loss of tolerance and the production of self-reactive autoantibodies by the humoral immune system are central to the pathogenesis of many glomerular diseases. These antibodies are produced by plasmablasts and plasma cells, the end products of B-cell lineage development within the bone marrow and secondary lymphoid tissues. In addition to antibody production, B cells also present antigen to T cells and produce proinflammatory cytokines. Nontargeted immunosuppression has shown efficacy in glomerular disease but is associated with multiple side effects, and there remains a high proportion of patients with resistant disease. In this article, we will review the biology of antibody-secreting cells and focus on therapeutics that specifically target B cells and plasma cells. We will review B-cell depletion strategies, including anti-CD20 monoclonal antibodies, B-cell–activating factor, and a proliferation-inducing ligand inhibition and B-cell receptor inhibition, highlighting their role in different glomerular diseases and outlining reasons for therapeutic resistance. We will also review plasma cell–directed therapies including proteasome inhibition and anti-CD38 therapies and discuss novel treatments including chimeric antigen receptor-T therapy and bispecific T-cell engagers.
- 4 June 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1844-1857
Targeting B Cells and Plasma Cells in Glomerular Disease
Loss of tolerance and the production of self-reactive autoantibodies by the humoral immune system are central to the pathogenesis of many glomerular diseases. These antibodies are produced by plasmablasts and plasma cells, the end products of B-cell lineage development within the bone marrow and secondary lymphoid tissues. In addition to antibody production, B cells also present antigen to T cells and produce proinflammatory cytokines. Nontargeted immunosuppression has shown efficacy in glomerular disease but is associated with multiple side effects, and there remains a high proportion of patients with resistant disease. In this article, we will review the biology of antibody-secreting cells and focus on therapeutics that specifically target B cells and plasma cells. We will review B-cell depletion strategies, including anti-CD20 monoclonal antibodies, B-cell–activating factor, and a proliferation-inducing ligand inhibition and B-cell receptor inhibition, highlighting their role in different glomerular diseases and outlining reasons for therapeutic resistance. We will also review plasma cell–directed therapies including proteasome inhibition and anti-CD38 therapies and discuss novel treatments including chimeric antigen receptor-T therapy and bispecific T-cell engagers.
- 8 December 2024
- Published by Taylor & Francis
- p. 90-98
Large- and Medium-Vessel Vasculitis
- 1 March 2023
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 30 (2) , 148-163
Physiology of a Forgotten Electrolyte—Magnesium Disorders
- 1 March 2023
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 30 (2) , 148-163
Physiology of a Forgotten Electrolyte—Magnesium Disorders
- 1 August 2021
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 78 (2) , 219-225.e1
Concurrent Anti–Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series
- 1 August 2021
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 78 (2) , 219-225.e1
Concurrent Anti–Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series